Bivalirudin anticoagulation for an infant with heparin resistance on ECMO: A case report

Siqi Guo,Lan Chen,Jing Shi,Ge Zhang
DOI: https://doi.org/10.1097/md.0000000000039357
IF: 1.6
2024-10-15
Medicine
Abstract:In recent decades, extracorporeal membrane oxygenation (ECMO) technology in the field of intensive care for children in China has developed rapidly, and it has become a key strategy for the rescue treatment of critically ill children and an advanced extracorporeal life support system. [ 1 ] Compared with adults and children, neonatal respiratory disease with ECMO support has the best prognosis, with an average survival rate of 74%. [ 2 ] Bleeding and thrombotic events during ECMO are common, morbid, and potentially lethal. Therefore, how to balance the coagulation state is the key to ECMO management. Continuous infusion of heparin is the first choice for ECMO anticoagulation, which should be used individually in the clinic. Activated clotting time (ACT), activated partial thromboplastin time (APTT), and anti-factor Xa (anti-Xa) are the preferred anticoagulation monitoring indicators. The anticoagulant effect of heparin is affected by the activity level of antithrombin III (AT-III) in the body (80%–120%). Infants with low AT-III are prone to heparin resistance. When heparin resistance or heparin-induced thrombocytopenia (HIT) occurs, instant adjustment of anticoagulation is needed. Bivalirudin, a direct thrombin inhibitor that inhibits reversibly binds thrombin without the cofactor AT-III. It has been used successfully for anticoagulation in patients on ECMO. However, it was used unconventionally in the neonatal population. There are few published data regarding bivalirudin anticoagulation for neonates on ECMO and no consistent coagulation monitoring protocol in the literature to date. [ 3 , 4 ]
medicine, general & internal
What problem does this paper attempt to address?